Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response.
Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D. Katlama C, et al. Among authors: bouchaud o. J Antimicrob Chemother. 2020 Dec 1;75(12):3699-3700. doi: 10.1093/jac/dkaa341. J Antimicrob Chemother. 2020. PMID: 32954404 No abstract available.
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Abgrall S, et al. Among authors: bouchaud o. Clin Infect Dis. 2007 Jan 1;44(1):120-7. doi: 10.1086/509578. Epub 2006 Nov 16. Clin Infect Dis. 2007. PMID: 17143827
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. Among authors: bouchaud o. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Loko MA, et al. Among authors: bouchaud o. Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10. Antivir Ther. 2012. PMID: 23052829
Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study.
Casalino E, Bernot B, Bouchaud O, Alloui C, Choquet C, Bouvet E, Damond F, Firmin S, Delobelle A, Nkoumazok BE, Der Sahakian G, Viard JP, Zbar OZ, Aslangul E, Krivine A, Zundel J, Ghosn J, Nordmann P, Claessens YE, Tahi T, Riou B, Gautheret-Dejean A, Katlama C, Hausfater P, Brun-Vézinet F, Costagliola D. Casalino E, et al. Among authors: bouchaud o. PLoS One. 2012;7(10):e46437. doi: 10.1371/journal.pone.0046437. Epub 2012 Oct 2. PLoS One. 2012. PMID: 23056308 Free PMC article.
388 results